ARWR - Arrowhead Pharma surges 16% on positive data from early-stage trial of inflammatory pulmonary diseases therapy

2023-04-25 10:43:30 ET

• Arrowhead Pharma ( NASDAQ: ARWR ) is trading ~16.4% higher after it announced interim results from an ongoing Phase 1/2 study of RNAi therapeutic, ARO-RAGE, to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma.
• The trial showed reductions in soluble RAGE as measured in serum after two doses on Day 1 and Day 29
• Mean maximum reduction at 92 mg dose was 80% with a maximum reduction of 90%.
• Mean maximum reductions at 10 to 44 mg dose levels showed a dose response ranging from 31% to 59%.
• Press Release

For further details see: